GLOBAL CANCER THERAPEUTICS AND BIOTHERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global Cancer Therapeutics And Biotherapeutics Market, By Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head and Neck Cancer, Giloblastoma, Malignant Meningioma, Mesothelioma, Melanoma, and Others), By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy, and Others), By Application (Therapeutics, Drug Discovery, Gene therapy, IVF treatment, Cell therapy, and Research & Development), By End User (Hospitals & Clinics, Cancer Care Centers, Research Institutes, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jul 2024
Code : CMI7206
Pages :175
Formats :
Excel and PDF
Industry : Biotechnology

Market Concentration and Competitive Landscape

Global Cancer Therapeutics And Biotherapeutics Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Growing awareness about cancer treatment

Cancer awareness across the globe has seen significant rise in recent years. Various non-profit organizations and governments are running widespread educational campaigns about cancer prevention, early detection and treatment options. This has boosted patient awareness about new therapeutic and biological treatment methods available for cancers. As people are more informed about biochemical and immune-based therapies, their preferences are shifting away from conventional chemotherapy towards more targeted and personalized approaches. Companies are continuously developing novel biologics and cell and gene therapies providing more efficacious and less toxic alternatives to existing standards of care. The success of some of the first approved CAR T-cell and oncolytic virus therapies have also increased confidence in these newer areas. The improved understanding of cancer at molecular level has accelerated the drug development pipeline. There are currently over 2500 biologics and immunotherapies under clinical trials globally according to figures from American Society of Clinical Oncology released in 2021. This extensive R&D activity when successful in gaining regulatory approvals will lead to substantial increase in the product offerings in the market. As awareness increases and more effective therapies become available, the majority of patients are opting for biologic and cell/gene therapy combinations or sequential treatments rather than chemotherapy alone. This shift towards personalized precision medicines is expected to significantly drive the revenues for cancer therapeutics and biopharmaceutical companies in the coming years. The market is anticipated to witness high growth rates fueled by this expanding treatment landscape and burgeoning demand for advanced therapeutic solutions.

Key Players Insights